GlassScriptPhysician profile
Marc A Swanson
NPI 1255350831
$7,545.97
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $1,437 · 2021: $1,594 · 2022: $1,362 · 2023: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,364.65 | 2021-2023 | Intellis Adaptivestim, Vanta Adaptivestim, Kyphon Express II Kyphopak Tray |
| Medtronic USA, INC. | $2,048.45 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $676.15 | 2019-2023 | Belbuca, Xtampza |
| Abbvie INC. | $664.71 | 2021-2023 | Qulipta, Ubrelvy, Botox |
| Depuy Synthes Sales INC. | $172.65 | 2019-2023 | Monovisc |
| Amgen INC. | $160.01 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $146.40 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $140.91 | 2019 | |
| Allergan, INC. | $121.24 | 2020-2021 | |
| Lilly USA, LLC | $97.07 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $91.30 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $87.68 | 2019-2021 | |
| Fidia Pharma USA INC. | $73.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $67.65 | 2019 | |
| Daiichi Sankyo INC. | $65.44 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $62.39 | 2020-2021 | |
| Eisai INC. | $56.48 | 2021 | |
| Assertio Therapeutics, INC. | $56.23 | 2019 | |
| Mdd US Operations, LLC | $55.31 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.49 | 2022 | |
| Si-Bone, INC. | $39.55 | 2020-2021 | |
| Bioventus LLC | $33.79 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $27.82 | 2023 | Xeomin |
| Currax Pharmaceuticals LLC | $26.30 | 2020-2022 | |
| Abbott Laboratories | $22.88 | 2021 | |
| Boston Scientific Corporation | $20.86 | 2022 | |
| Lundbeck LLC | $18.84 | 2022 | |
| Grt US Holding, INC. | $18.57 | 2021 | |
| Horizon Therapeutics Plc | $16.00 | 2020 | |
| Kci USA, INC. | $15.17 | 2020 | |
| Shionogi INC | $13.97 | 2019 | |
| Zyla Life Sciences, INC. | $13.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.83 | 2019 | |
| Pfizer INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.